Related Experiment Video
Updated: May 2, 2026

An Ex vivo Model to Study Hormone Action in the Human Breast
Published on: January 8, 2015
Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells
Gwen E Dressing1, Todd P Knutson, Matthew J Schiewer
1Departments of Medicine and Pharmacology (G.E.D., T.P.K., A.R.D., C.R.H., C.H.D., C.A.L.), Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455; and Departments of Cancer Biology, Urology, and Radiation Oncology (M.J.S., K.E.K.), Kimmel Cancer Center Thomas Jefferson University, Philadelphia, Pennsylvania 19107.
Abstract:
The progesterone receptor (PR) and its coactivators are direct targets of activated cyclin-dependent kinases (CDKs) in response to peptide growth factors, progesterone, and deregulation of cell cycle inhibitors. Herein, using the T47D breast cancer model, we probed mechanisms of cell cycle-dependent PR action. In the absence of exogenous progestin, the PR is specifically phosphorylated during the G2/M phase. Accordingly, numerous PR target genes are cell cycle regulated, including HSPB8, a heat-shock protein whose high expression is associated with tamoxifen resistance. Progestin-induced HSPB8 expression required cyclin D1 and was insensitive to antiestrogens but blocked by antiprogestins or inhibition of specificity factor 1 (SP1). HSPB8 expression increased with or without ligand when cells were G2/M synchronized or contained high levels of cyclin D1. Knockdown of PRs abrogated ligand-independent HSPB8 expression in synchronized cells. Notably, PRs and cyclin D1 copurified in whole-cell lysates of transiently transfected COS-1 cells and in PR-positive T47D breast cancer cells expressing endogenous cyclin D1. PRs, cyclin D1, and SP1 were recruited to the HSPB8 promoter in progestin-treated T47D breast cancer cells. Mutation of PR Ser345 to Ala (S345A) or inhibition of CDK2 activity using roscovitine disrupted PR/cyclin D1 interactions with DNA and blocked HSPB8 mRNA expression. Interaction of phosphorylated PRs with SP1 and cyclin D1 provides a mechanism for targeting transcriptionally active PRs to selected gene promoters relevant to breast cancer progression. Understanding the functional linkage between PRs and cell cycle regulatory proteins will provide keys to targeting novel PR/cyclin D1 cross talk in both hormone-responsive disease and HSPB8-high refractory disease with high HSPB8 expression.
Insights
Cyclin-dependent kinases (CDKs) target progesterone receptors (PRs), influencing cell cycle-regulated gene expression like HSPB8. This interaction, involving cyclin D1 and SP1, is crucial for breast cancer progression and tamoxifen resistance.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Progesterone receptor (PR) and coactivators are targeted by activated cyclin-dependent kinases (CDKs).
- CDK activity is influenced by growth factors, progesterone, and cell cycle inhibitors.
- PR action is linked to the cell cycle, impacting gene expression.
Purpose of the Study:
- To investigate cell cycle-dependent progesterone receptor (PR) mechanisms in breast cancer.
- To elucidate the role of PR phosphorylation and coactivators in gene regulation.
- To understand the link between PR, cell cycle proteins, and breast cancer progression.
Main Methods:
- Utilized the T47D breast cancer cell model.
- Investigated PR phosphorylation during the G2/M phase.
- Analyzed HSPB8 gene regulation by PR, cyclin D1, and SP1.
- Employed co-purification, chromatin immunoprecipitation, and gene knockdown techniques.
- Assessed the impact of CDK inhibition (roscovitine) and PR mutation (S345A).
Main Results:
- PR is phosphorylated during G2/M phase, regulating target genes like HSPB8.
- HSPB8 expression is cell cycle-regulated, linked to tamoxifen resistance.
- Progestin-induced HSPB8 expression requires cyclin D1 and SP1, independent of antiestrogens.
- PRs and cyclin D1 co-purify and bind to the HSPB8 promoter with SP1.
- CDK2 inhibition or PR S345A mutation disrupts PR/cyclin D1-DNA interaction and blocks HSPB8 expression.
Conclusions:
- Phosphorylated PRs interact with SP1 and cyclin D1, targeting transcriptionally active PRs to gene promoters.
- This interaction is critical for genes involved in breast cancer progression.
- Understanding PR and cell cycle protein crosstalk offers therapeutic targets for hormone-responsive and refractory breast cancers.
More Related Videos
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
10:36Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
Related Concept Videos
Negative Regulator Molecules
Positive Regulator Molecules
Positive Regulator Molecules
Inhibition of Cdk Activity
Inhibition of CDK Activity
Mitogens and the Cell Cycle